These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22189487)

  • 1. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
    Garrone O; Crosetto N; Lo Nigro C; Catzeddu T; Vivenza D; Monteverde M; Merlano M; Feola M
    Cardiovasc Toxicol; 2012 Jun; 12(2):135-42. PubMed ID: 22189487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].
    Huang WB; Yao GY; Liu MF; Chen RT; Chen LJ; Dong JY; Gu F; Guo ZZ; Ye CS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1047-50. PubMed ID: 21690066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
    Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
    Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
    Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
    Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.
    Pichon MF; Cvitkovic F; Hacene K; Delaunay J; Lokiec F; Collignon MA; Pecking AP
    In Vivo; 2005; 19(3):567-76. PubMed ID: 15875778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
    Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
    Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
    Vivenza D; Feola M; Garrone O; Monteverde M; Merlano M; Lo Nigro C
    Int J Biol Markers; 2013 Dec; 28(4):e336-47. PubMed ID: 23999848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
    Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
    Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
    Nagy AC; Tolnay E; Nagykálnai T; Forster T
    Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
    Morris PG; Chen C; Steingart R; Fleisher M; Lin N; Moy B; Come S; Sugarman S; Abbruzzi A; Lehman R; Patil S; Dickler M; McArthur HL; Winer E; Norton L; Hudis CA; Dang CT
    Clin Cancer Res; 2011 May; 17(10):3490-9. PubMed ID: 21372222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
    Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
    Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer].
    Oberholzer K; Kunz RP; Dittrich M; Thelen M
    Rofo; 2004 Sep; 176(9):1245-50. PubMed ID: 15346258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.